The Arkansas Supreme Court has thrown out a $1.2 billion judgment against Johnson & Johnson in a lawsuit challenging its marketing of the antipsychotic drug Risperdal.

The Thursday ruling comes in an appeal of lawsuit filed by Arkansas against the drugmaker and subsidiary Janssen Pharmaceuticals. The state says the companies didn't properly communicate the drug's risks and marketed it for off-label use, calling the practices fraudulent.